Maxim Group analyst Jason McCarthy reiterated a Buy rating on Iterum Therapeutics today and set a price target of $5.00. The company’s shares closed yesterday at $0.67.Elevate Your Investing Strategy:...
Iterum Therapeutics confirms compliance with Nasdaq listing requirements, allowing continued trading of its stock.Quiver AI SummaryIterum Therapeutics plc announced that it has resolved its compliance...
--SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections-- --Clinical Trial...
DUBLIN, Ireland and CHICAGO, July 06, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical...
DUBLIN, Ireland and CHICAGO, June 14, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical...
NEW YORK, NY / ACCESSWIRE / October 4, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate...
NEW YORK, NY / ACCESSWIRE / October 4, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate...
NEW YORK, NY / ACCESSWIRE / October 4, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders...
NEW YORK, NY / ACCESSWIRE / October 4, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders...
NEW YORK, NY / ACCESSWIRE / October 3, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate...